Surefire Precision Infusion System Registry

Stopped early

Conditions studied: Hepatocellular Carcinoma

In brief

This project involves the collection and analysis of retrospective and prospective data on patients diagnosed with hepatocellular carcinoma (HCC) in which the Surefire Precision Infusion System was used/will used be to deliver transarterial chemoembolization with doxorubicin-eluting beads (DEB-TACE). The purpose is to compare tumor and medical response in a real-world setting as well as identify potential areas for future clinical research.

Key facts

Study ID
NCT02967523
Run by
Surefire Medical, Inc.
People needed
111
Starts
2016-05-01
Expected to finish
2018-06-18
Last updated by the study team
2018-09-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.